Equity Overview
Price & Market Data
Price: $1.89
Daily Change: -$0.07 / 3.70%
Range: $1.85 - $2.02
Market Cap: $68,372,832
Volume: 176,598
Performance Metrics
1 Week: -10.80%
1 Month: 50.79%
3 Months: 18.75%
6 Months: -12.44%
1 Year: 12.43%
YTD: -13.64%
Company Details
Employees: 66
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.